Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention ICON plc, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention ICON plc, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. At 6, the average consequence score sits above the same-window beat average of 5.9. Advarra appears in 1 tracked Biotech story from March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Advarra. Shared-story counts are live from our verified record — not editorial picks.
Performance Review
Analysis of startup timeline improvements and data quality metrics.
Initial Implementation
Rollout of the model across select ICON-managed clinical trials.
Model Launch
ICON and Advarra officially introduce the Research-Ready, Connected Site Network Model.
Network Expansion
Onboarding of additional sites into the 'Research-Ready' ecosystem.
ICON plc and Advarra have introduced a new 'Research-Ready, Connected Site Network Model' designed to bridge the gap between clinical research sites and sponsors. The partnership aims to reduce trial startup timelines and administrative burdens through integrated technology and standardized workflows.
Advarra is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
